Summary: Genmab Reveals That HuMax-Inflam Target is IL-8 and Future
Development Will be in Cancer and Inflammation
COPENHAGEN, September 13 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today its fully human HuMax-Inflam(TM) antibody is directed to IL-8 (interleukin-8) and may have potential application in oncology and inflammation. Genmab will initially focus on studies to treat glioblastoma, a cancer of the central nervous system. Other possible indications include chronic obstructive pulmonary disease (COPD) and pustular dermatoses. In pre-clinical studies, HuMax-Inflam has been shown to inhibit tumor growth in tumor models using primary human tumors in immunodeficient mice. HuMax-Inflam was also effective in reducing disease activity in palmoplantar pustulosis patients in a clinical study.
Genmab is currently preparing an improved commercially viable cell line for HuMax-Inflam and hopes to start the next phase of clinical trials in 2008.
"Genmab's development plans for HuMax-Inflam have been a closely guarded secret for several years now and we are happy to announce the solution to the mystery, which has been much anticipated by the investment community," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "We believe that HuMax-Inflam may have potential to treat patients with glioblastoma, which has a very low survival rate."
About HuMax-Inflam and IL-8
HuMax-Inflam is a high affinity fully human IgG1,k antibody directed
towards IL-8. IL-8 is a major mediator of inflammation, a potent
chemoattractant for white blood cells called neutrophils, as well as an
important factor in angiogenesis. HuMax-Inflam effectively blocks binding
of IL-8 to neutrophils and inhibits neutrophils from migrating towards
sites of inflammation via a process known as chemotaxis. HuMax-Inflam also
potently inhibits IL-8 induced neutrophil activation. In pre-clinical
studies, HuMax-Inflam has been shown to inh
|SOURCE Genmab A/S|
Copyright©2007 PR Newswire.
All rights reserved